In response to the Office Action dated October 8, 2002, in the above-identified U.S. Patent application, please amend the application as follows:

In the Specification

Please amend the specification as follows:

On page 3, the first paragraph should read as follows:

B1

In a preferred embodiment, a p53 binding region comprises the sequence of figure 4, (p53 Be sequence) (SEQ ID NO. 24) and/or figure 5 (SEQ ID NOs. 12, 14 and 16) (one or more of the p53 Be sequences) or a sequence differing therefrom by one or more base pairs. The expression "a sequence differing by one or more base pairs" comprises a sequence of a CD95 receptor DNA which hybridizes with the DNA of figure 4 (SEQ ID NOs. 24 and 32) and/or figure 5 (SEQ ID NO. 12, 14 and 16) and to which a p53 may bind and which may activate the CD95 receptor DNA. The sequence may differ from the DNA of figure 4 and/or figure 5 by additions, deletions, substitutions and/or inversions of one or more base pairs. The expression "hybridization" refers to hybridization under common conditions, in particular at 20°C below the melting point of the sequence.

On page 3, the second paragraph should read as follows:

B2

In a particularly preferred embodiment a p53 binding region comprises the sequence of figures 7, (SEQ ID NO. 2), 8 (SEQ ID NO. 3), 9 (SEQ ID NO. 4), 10 (SEQ ID NO. 1), 11 (SEQ ID NOs. 6, 7, 8, and 9), 12 (SEQ ID NOs. 11, 13, 15, 17 and 19) or 13 (SEQ ID NOs. 25, 27, 29 and 31), the sequence of figures 11, 12, and 13 being variations of the sequences of figures 8, 9 and 10, respectively. Furthermore, the sequences of figures 7, 8, 9 and 10 are explained in figure 14.

On page 10, the fifth paragraph should read as follows:

B3

CD95 (Ps)-LUC

The luciferase-DNA is linked via its 5' end with a 1.43 kb promoter region and the 5' end of exon 1 of the CD95 receptor DNA (HindIII-SacII fragment, cf. figures 5 (SEQ ID NOs. 12, 14 and 16) and 6).

On page 10, the sixth paragraph should read as follows:

B4

CD95(P)-LUC

The luciferase DNA is linked via its 5' end with a 1.9 kb promoter region and the 5' end of exon 1 of CD95 receptor DNA (cf. figures 5 (SEQ ID NOs. 12, 14 and 16) and 6).

On page 10, the seventh paragraph should read as follows:

B5

CD95(I+SV)-LUC

The luciferase DNA is linked via its 5' end with the "minimum" SV40 promoter and a 0.7 kb intron 1 fragment of the CD95 receptor DNA (cf. figures 4 (SEQ ID NOs. 24 and 32) and 6).

On page 11, the first paragraph should read as follows:

B6

The luciferase DNA is linked via its 5' end with a 0.7 kb intron 1 fragment and a 1.43 kb promoter region of the CD95 receptor DNA (cf. figures 4 (SEQ ID NOs. 24 and 32) and 6).

In the Claims:[1]

Please amend claims 1, 2, 4 and 6 – 11 to read as follows:

B7

1. An isolated p53 binding region of a human CD95 receptor DNA, wherein p53 may activate the CD95 receptor DNA by binding to the p53 binding region, the isolated p53 binding region comprising SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 1, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 29, SEQ ID NO. 31, SEQ ID NO. 24 or SEQ ID NO. 32.

[1] Consistent with the requirements of 37 C.F.R. §1.121, a marked up version of the amended claims is contained in Appendix A hereof; a clean copy of all pending claims is contained in Appendix B hereof. Consistent with the holding of Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., et al., 535 U.S. ___ (2002), decided May 28, 2002, any amendments herein that hereafter are deemed to be narrowing amendments by a court of competent jurisdiction in a final unappealed or unappealable decision, are not intended to relinquish any scope of equivalents unforeseeable at the time of this amendment or that relate to aspects of the invention having only a peripheral relation to the basis for the amendment.